Deep learning to provide insights in pulmonary fibrosis trial
Qureight and Avalyn Pharma have announced the initiation of a strategic partnership in progressive pulmonary fibrosis, commencing with the ongoing MIST study. The MIST study is a Phase IIb clinical trial evaluating the safety and efficacy of AP01 (inhaled pirfenidone) in patients with progressive pulmonary fibrosis (PPF). Read More